Company: STAA
Filing Date: 2025-12-16
Form Type: DFAN14A
Source: 0001213900-25-122330
Chunk: 4

Company: STAAR SURGICAL CO
Filing Date: 2025-12-16
Form: DFAN14A
Chunk 4
---
 changes to STAAR’s
leadership group.

It is a sad day when the best argument
for agreeing to the sale of a company is that the leadership team and board are so unreliable and lacking in credibility that shareholders
cannot count on strong execution or proper stewardship in the future. Notwithstanding the Board and leadership team’s failures of
oversight and execution, we remain confident in STAAR’s product and market opportunity and believe STAAR is worth substantially
more than Alcon is offering today.

Notably, just last year, Alcon offered
twice as much for the Company, and STAAR’s long-term prospects have not changed meaningfully. Since this misbegotten transaction
was proposed, STAAR has downplayed its own performance and future opportunity – at every turn – to justify the deal. However,
as ISS noted, shareholders have no reason to trust the judgment or integrity of STAAR’s Board in making a determination about the
deal consideration, and the Board chose not to seek advice from its financial advisor regarding the fairness of Alcon’s revised
proposal.

Shareholders should not throw in the
towel at a discounted price just because they cannot trust the current Board and management team to properly run the Company or a sale
process. Nor should shareholders reward a misaligned and poorly performing management team and conflicted Board with a lucrative exit.
What message would that send to all other boards?

We are taking the necessary steps to
call a special meeting of shareholders to remove the three directors we feel are most responsible for this deeply flawed and conflicted
transaction. We also remain prepared to work with our fellow shareholders to identify qualified independent and experienced director candidates
to ensure that STAAR is positioned to succeed and maximize value for all shareholders.”

Broadwood encourages its fellow shareholders to
review its presentations, proxy materials, and press releases, all of which are available at www.LetSTAARShine.com, and to vote “AGAINST”
the proposed transaction with Alcon.

If you have any questions or require any assistance
with voting your shares, please contact our proxy solicitor, Saratoga Proxy Consulting LLC, by calling (212) 257-1311 or toll free at
(888) 368-0379, or by email at info@saratogaproxy.com. If you have already voted for the merger, you may change your vote by voting a
later-dated proxy “AGAINST” the deal. Only your latest dated vote counts.

About Broadwood

Broadwood Partners, L